Rose bengal sodium - Provectus Biopharmaceuticals

Drug Profile

Rose bengal sodium - Provectus Biopharmaceuticals

Alternative Names: PH-10; Provecta; PV-10; Rose bengal; Rose bengal disodium; Rose bengal sodium I 125; Rose bengal sodium I 131; Xantryl

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Photogen Technologies Inc.
  • Developer Pediatric Oncology Experimental Therapeutics Investigators Consortium; Provectus Biopharmaceuticals
  • Class Antineoplastics; Antipsoriatics; Antivirals; Fluoresceins; Small molecules
  • Mechanism of Action Cell death stimulants; Cell membrane modulators; Dendritic cell stimulants; Immunostimulants; Interferon modulators; Interleukin 17 modulators; Interleukin-22 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Atopic dermatitis; Cancer; Psoriasis

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Atopic dermatitis; Psoriasis
  • Phase I Hepatocellular carcinoma; Liver metastases; Neuroendocrine tumours
  • Preclinical Cancer
  • Discontinued Acne vulgaris; Breast cancer

Most Recent Events

  • 27 Dec 2017 Phase-III clinical trials in Malignant melanoma (Late-stage disease, Metastatic disease) in Italy and Germany (Intralesional) (NCT02288897)
  • 18 Dec 2017 Phase I development is ongoing for Hepatocellular carcinoma and Liver metastases in USA (NCT00986661) (Provectus pipeline, December 2017)
  • 14 Dec 2017 Provectus Biopharmaceuticals and Pfizer have patent protection for the use of PV 10 in combination with systemic immunotherapy agents for multiple solid tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top